About Beth Klein

Denver Attorney, Beth KleinBeth Klein is Founder & Managing Shareholder at Klein & Frank, P.C., a personal injury law firm based in Denver, Colorado. She is licensed to practice law in Colorado, California, and Texas and admitted to practice in federal courts in Colorado, Kentucky, Illinois, Ohio, Utah, and in the Tenth Circuit.

Mrs. Klein is rated as an "A-V" lawyer, preeminent lawyer, by the Martindale-Hubbell Law Directory, the oldest and most prestigious attorney rating service in the U.S.

Beth was selected as one of the 500 Leading Plaintiff's Lawyers in the United States by Lawdragon in 2006. She was awarded the 21 Leaders Award from Womens E News for being an advocate for the enslaved and for writing effective anti-human trafficking law, pro bono. In 2011 More Magazine named Beth Klein as one of the 50 Women That You Want On Your Side along with Michelle Obama, Oprah Winfrey, Hillary Clinton and many other women world leaders. She has written laws for many states and works with nations around the world to end slavery through law.

In the 90s, Beth was personally selected to serve as National Trial Counsel to Owens Corning in a high-profile series of asbestos litigation cases. She represented corporations in high-risk cases (cases that had a potential jury award of $5 million or more) until she was asked by the plaintiff's counsel to change sides and represent people who had been diagnosed with asbestos related cancer and mesothelioma.

Beth is a Fellow of the Colorado Bar Foundation, and is a Member of the Million Dollar Advocates and a Fellow of the Litigation Counsel of America.

    Find more about this author on:
  • googleplus
  • linkedin

Here are the author's recent posts:

Gadolinium Health Alert

Information coming to light about gadolinium use as a contrast agent indicates that for people with renal failure or kidney transplants, the very diagnostic test used to cure, may result in devastating injuries or death.

Medical Device Litigation 101

The FDA governs medical devices for use and sale in the United States, and was given power over medical devices in the 1976 Medical Device Amendments to the Food, Drug, & Cosmetic Act, 21 U.S.C. section 360c et seq.